By publishing the methodology before you publish the headline. A company study gets covered when a journalist can check how you got the number, and gets ignored when they cannot. That is the whole difference, and it is a documentation problem more than a writing problem. There is also a trap specific to peer-reviewed research, where announcing results early can cost you the journal.
What makes a company study newsworthy rather than content marketing?
A finding that could have come out the other way. If the result of your survey is that buyers in your category want better software, you have produced a brochure with percentages in it. Journalists can tell the difference immediately, because a study designed to confirm your pitch has no information in it.
Three kinds of finding reliably earn attention. A result that contradicts the consensus in your sector, stated plainly and with the numbers to back it. A dataset nobody else can produce, usually because it comes from your own operations rather than a panel. And a measurement of something people argue about without evidence, where you are the first to put a number on it. Everything else is content, which can be a perfectly good use of your time, just not a press story. The same logic that governs what counts as news in a product launch applies here.
What methodology do you have to disclose before a journalist will cite you?
More than most companies publish, and the standard is written down. The American Association for Public Opinion Research's Code of Professional Ethics and Practices states that "good professional practice imposes the obligation upon all public opinion and survey researchers to disclose sufficient information about how the research was conducted to allow for independent review and verification of research claims, regardless of the methodology used in the research."
The Code's items for immediate disclosure, meaning disclosed at the time results are released rather than on request, include the data collection strategy, who sponsored the research and who conducted it, the measurement tools and the exact wording of the questions asked, the population under study, and the method used to generate and recruit the sample. On sponsorship it is specific: name the sponsor and the parties who conducted it, and "if the original source of funding is different than the sponsor, this source will also be disclosed." A further set of items has to be released within 30 days of any request.
In practice that means a methodology note, published on your own site at the same moment as the announcement, covering: who was asked, how many, how they were recruited, whether the sample was probability-based or opt-in, when fieldwork ran, who paid, and the exact question wording. Reporters at serious outlets look for this before they decide whether your number is usable, and a release that omits the sample size and the fielding dates reads as something to be avoided rather than quoted.
One honest consequence: if your survey polled 180 self-selected customers, disclosing that properly will cost you some coverage. It will also stop you being the company whose number gets publicly pulled apart six months later.
Why can announcing peer-reviewed results early cost you the publication?
Because most journals treat prepublication publicity as grounds to decline the paper, and this surprises companies with a research arm almost every time.
The International Committee of Medical Journal Editors describes the mechanism directly. Journals operate an embargo system "to prevent publication of stories in the general media before publication of the original research in the journal," and this "can be accomplished by an agreement with authors that they will not publicize their work while their manuscript is under consideration or awaiting publication."
Read that carefully: the restriction starts when you submit, not when the paper is accepted. A press release, a conference talk with the full results, or a founder's post summarizing the findings can all qualify as publicizing work that is under consideration.
The exception is narrow and not yours to invoke. ICMJE says "very little medical research has such clear and urgently important clinical implications for the public's health that the news must be released before full publication in a journal," and where it does, "the appropriate authorities responsible for public health should decide whether to disseminate information to physicians and the media in advance."
The practical sequence, then: submit, say nothing, and work with the journal's own press office on a coordinated embargoed release timed to publication. That gets you the coverage and the paper. Doing it in the other order can get you neither.
What happens when the finding touches a health or performance claim?
The evidentiary bar rises, and it is not set by your marketing team's confidence. The US Federal Trade Commission's Health Products Compliance Guidance requires that "before disseminating an ad, advertisers must have adequate substantiation for all objective product claims conveyed, expressly or by implication, to consumers acting reasonably," and defines the standard as "tests, analyses, research, or studies that (1) have been conducted and evaluated in an objective manner by experts in the relevant disease, condition, or function to which the representation relates; and (2) are generally accepted in the profession to yield accurate and reliable results."
Two details matter for anyone planning to announce a single study. The guidance notes that "the replication of research in an independently-conducted study adds to the weight of the evidence," and that "numerous flawed and inadequate studies are unlikely to add up to competent and reliable scientific evidence." Quantity does not substitute for quality. The guidance also warns that marketers "may be legally responsible for claims implied by their reference either directly or indirectly to third-party literature," which covers the common tactic of citing someone else's research to imply something about your own product.
If you are communicating about health in the UAE specifically, there is a separate approvals layer on the advertising side, which we cover in our note on how DHA and MOHAP advertising approval differs from earned healthcare PR. None of this is legal advice, and a regulated claim should go past your own counsel before it goes anywhere near a journalist.
How should you sequence the announcement?
Publish the full report and the methodology note on your own site first, at a stable URL. Then pitch the finding, not the report, to a short list of reporters who cover that subject, with the specific number in the first two lines and the methodology linked. If one outlet matters more than the rest, offer it the finding ahead of everyone else rather than sending the same release to forty inboxes, which is the distinction we draw in our piece on whether a press release is the right tool at all.
Then measure it as coverage rather than as a download count. A research report that produces 400 gated downloads and no independent citations has not done the job a study is for, which is to make other people repeat your number. Our guide to measuring whether PR is working sets out the tiers that distinguish the two.
What should you avoid?
- Burying the sponsor. AAPOR's Code requires naming both the sponsor and the funder. Readers and reporters find this out anyway, and finding it out late is worse than reading it in the methodology note.
- Calling a 180-person opt-in poll "research." Describe what it is. A small sample honestly labeled is quotable; a small sample dressed up as a study is a liability.
- Rounding toward the story. If 48% becomes "nearly half" in the release and "most" in the social post, the number has stopped being evidence.
- Announcing before submission to a journal. See above. This one is irreversible.
The direct answer, for anyone who read this far
Lead with a finding that could have gone the other way, and publish the methodology alongside it. AAPOR's Code obliges researchers to disclose enough about how the work was done "to allow for independent review and verification of research claims," including sponsor, funder, sample, recruitment method, question wording and fielding dates, at the moment of release. If the work is going to a peer-reviewed journal, say nothing publicly from the day you submit, because ICMJE's standard asks authors not to publicize work while it is under consideration. And if the finding implies a health or performance benefit, the FTC's substantiation standard, not your confidence, decides whether you can say it.
If you have a study sitting in a drawer because nobody is sure how to take it to press, request a quotation and we will tell you whether the finding is strong enough to carry a story.
